

# **IDOSE TR- travoprost intracameral implant**

## **Glaukos Corporation**

-----

### **HIGHLIGHTS OF PRESCRIBING INFORMATION**

**These highlights do not include all the information needed to use iDose® TR safely and effectively. See full prescribing information for iDose® TR.**

**iDose® TR (travoprost intracameral implant), for intracameral administration**  
**Initial U.S. Approval: 2001**

### -----**RECENT MAJOR CHANGES**-----

Dosage and Administration (2.1, 2.2, 2.3, 2.4, 2.5)	1/2026
Warnings and Precautions (5.3, 5.4, 5.5)	1/2026

### -----**INDICATIONS AND USAGE**-----

iDose® TR is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) (1)

### -----**DOSAGE AND ADMINISTRATION**-----

- For ophthalmic intracameral administration (2.1)
- The intracameral administration should be carried out under standard aseptic conditions (2.2)

### -----**DOSAGE FORMS AND STRENGTHS**-----

Intracameral implant containing 75 mcg travoprost, pre-loaded in a single-dose inserter (3)

### -----**CONTRAINDICATIONS**-----

- Ocular or periocular infections (4.1)
- Corneal endothelial dystrophy (4.2)
- Prior corneal transplantation (4.3)
- Hypersensitivity (4.4)

### -----**WARNINGS AND PRECAUTIONS**-----

- Iridocorneal Angles: iDose TR should be used with caution in patients with narrow angles or other angle abnormalities (5.1)
- Device Dislocation: Monitor patients routinely to confirm the location of the iDose TR at the site of administration (5.2)
- Pigmentation: Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent (5.8)

### -----**ADVERSE REACTIONS**-----

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, and visual field defects (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Glaukos Corporation at 1-888-404-1644 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**See 17 for PATIENT COUNSELING INFORMATION.**

**Revised: 1/2026**

---

## **FULL PRESCRIBING INFORMATION: CONTENTS\***

### **1 INDICATIONS AND USAGE**

### **2 DOSAGE AND ADMINISTRATION**

- 2.1 General Dosing Information
- 2.2 Administration Instructions
- 2.3 Evaluation and Testing Before Readministering iDose TR
- 2.4 Readministration Instructions
- 2.5 Frequency of Readministration

### **3 DOSAGE FORMS AND STRENGTHS**

### **4 CONTRAINDICATIONS**

- 4.1 Ocular or Periocular Infections
- 4.2 Corneal Endothelial Dystrophy
- 4.3 Prior Corneal Transplantation
- 4.4 Hypersensitivity

### **5 WARNINGS AND PRECAUTIONS**

- 5.1 Iridocorneal Angles
- 5.2 Device Dislocation
- 5.3 Patients without Baseline Corneal Endothelial Cell Density Prior to Initial Administration
- 5.4 Recommended Minimum Corneal Endothelial Cell Density for Readministration
- 5.5 Corneal Endothelial Cell Loss
- 5.6 Macular Edema
- 5.7 Intraocular Inflammation
- 5.8 Pigmentation
- 5.9 Endophthalmitis
- 5.10 Magnetic Resonance Imaging (MRI) Conditional

### **6 ADVERSE REACTIONS**

- 6.1 Clinical Trials Experience

### **8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

### **11 DESCRIPTION**

### **12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics

### **13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### **14 CLINICAL STUDIES**

### **16 HOW SUPPLIED/STORAGE AND HANDLING**

### **17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

iDose<sup>®</sup> TR (travoprost intracameral implant) is indicated for the reduction of intraocular

pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

## 2 DOSAGE AND ADMINISTRATION

### 2.1 General Dosing Information

iDose TR is a travoprost delivery system consisting of a travoprost releasing implant pre-loaded in a sterile, single-dose inserter. iDose TR is administered intracamerally through a small, clear corneal incision and is anchored into the sclera at the iridocorneal angle.

### 2.2 Administration Instructions


1. The procedure must be carried out under aseptic conditions which include use of sterile gloves and a sterile drape.
2. The eye should be anesthetized using general, retrobulbar, peribulbar, or topical anesthesia per standard operating room procedures.
3. The iDose TR implantation procedure must be performed under magnification that allows clear visualization of the anterior chamber angle and angle structures including trabecular meshwork, with the patient's head in a stabilized position. The pupil should not be dilated prior to the procedure.
4. An intracameral miotic can be injected to deepen the angle prior to insertion of the iDose TR.
5. It is recommended that the implant surgery be performed from the temporal side, using a temporal clear corneal incision. The implant will be implanted through the angle and the trabecular meshwork into the sclera on the nasal side.
6. Remove the barrier pouch from the carton and examine for damage. Open the barrier pouch, discard the oxygen scavenger packet, and remove the blister tray with Tyvek<sup>®</sup> lid. Open the Tyvek lid containing the iDose TR pre-loaded inserter and present to the surgeon. The iDose TR implant and single-dose inserter should be handled in the sterile field. **Caution:** Do not use the iDose TR if the Tyvek lid has been opened or the packaging appears damaged.
7. Prepare for gonioscopy by turning the patient's head away from the surgeon by approximately 15° to 25° and tilt the scope toward the surgeon by approximately 35°. The total combined angle should be approximately 50° to 60°.
8. Place a small amount of viscoelastic on the cornea. Position the gonioprism on the cornea using light touch gonioscopy. Adjust the microscope to locate and focus on the trabecular meshwork.
9. Inspect the angle with a gonioprism to ensure that a good view of all angle structures is available at the nasal implant location.
10. Hold the single-dose inserter with your index finger comfortably on the implant release button (see **Figure 1**)

#### Figure 1



11. Perform a detailed inspection of the tip of the sterile inserter under magnification to ensure that the iDose TR implant is present (see **Figure 2**).

**Figure 2**




12. Create a clear corneal incision of approximately 2.4 mm at the temporal limbus location using an instrument of the surgeon's choice.

13. Add a cohesive viscoelastic to the anterior chamber as needed to form the anterior chamber and improve visualization of the angle. Be careful not to overinflate.

**14. Insertion of the implant:**


- a. When ready for implantation, remove the safety clip which holds the release button in place by squeezing and rocking the clip backwards (see **Figure 2**). Place finger on the release button to ensure it remains in the forward position and does not prematurely release the implant.
- b. To smoothly enter the anterior chamber, slide the inserter tip with implant "side to side" in the incision.
- c. Advance to the pupillary margin and ensure there is sufficient cohesive viscoelastic on the cornea before replacing the gonioprism onto the cornea.
- d. Take care to avoid contact with the lens or cornea.
- e. Advance to the anterior chamber angle and approach the trabecular meshwork (see **Figure 3**).

**Figure 3**




- f. Press the implant directly through the trabecular meshwork, compressing the tissue until the implant anchor securely penetrates the sclera through the back wall of Schlemm's canal. The base of the implant reservoir should be firmly in contact with and compressing the trabecular meshwork.
- g. Once the anchor of the implant is securely embedded in sclera, pause for the tissue to relax. Carefully slide the implant release button backwards to open the inserter tip with grasper and release the implant from the inserter (see **Figure 4a**). Ensuring the implant has released from the inserter grasper, slowly remove the inserter straight back (see **Figure 4b**). Avoid pulling the implant out of position.

**Figure 4a**



**Figure 4b**




h. Apply slight pressure to the sides of the implant with the tip of the inserter to ensure the implant is fully anchored into scleral tissue. Note: If for any reason the implant appears loose or disengaged from the scleral tissue after the initial implantation, slide the implant release button back to fully open the graspers. Position the graspers between the ribs on the implant and regrasp the body of the implant between the ribs by pushing the release button forward and re-implant a minimum of  $\frac{1}{2}$  clock hour to either side. Do not re-implant at the same location.

i. Withdraw the inserter from the eye.

### 15. Location of iDose TR in Trabecular Meshwork

a. Perform a high-magnification examination to confirm that the implant is in proper position (i.e., the proximal end rests in the anterior chamber with an unobstructed membrane) (see **Figure 5**) and securely attached with the anchor thoroughly embedded in the sclera.

**Figure 5**



b. It is normal for an edge of the implant to make contact with the iris. Note: In a normal iris (no viscoelastic in the anterior chamber and non-constricted pupil), the iris may obstruct the view of a portion of the cap of the implant.

c. Irrigate and aspirate the anterior chamber with balanced salt solution to remove all viscoelastic. Press down on the posterior edge of the incision as needed to facilitate complete removal of viscoelastic.

d. Inflate the anterior chamber with saline solution as needed to achieve physiologic pressure.

### 2.3 Evaluation and Testing Before Readministering iDose TR

Perform specular microscopy to evaluate the corneal endothelium and establish pre-implantation baseline corneal endothelial cell density prior to the initial administration of iDose TR and prior to each readministration [see *Warnings and Precautions (5.4)*].

**Table 1** describes readministration modifications if specific adverse reactions have occurred [see *Contraindications (4)*, *Warnings and Precautions (5.2, 5.5)*].

**Table 1: Dosage (Readministration) Modifications for Adverse Reactions**

<b>Adverse Reactions</b>	<b>Dosage Modification</b>
Ocular or periocular infections	Withhold dose (readministration)
Prior iDose TR device dislocation	Withhold dose (readministration)
Central corneal endothelial cell loss of 10% or greater from pre-administration baseline (adjusted for age-related 1% loss per year and for a 10% loss following an anterior segment surgical procedure [e.g., cataract surgery])	Withhold dose (readministration)

## 2.4 Readministration Instructions

**Note:** When readministering an iDose TR implant, always remove the previous iDose TR implant **AFTER** implantation of the new implant.

1. Follow "Administration Instructions" Steps 1 to 13 [see *Dosage and Administration (2.2)*].
2. Assure the anterior chamber is fully formed with a cohesive viscoelastic. If you notice a soft eye, or a shallow anterior chamber, re-inflate. If needed, apply cohesive viscoelastic directly on the previous implant while inflating to remove any loose tissue, iris strands, or debris.
3. Insert the new iDose TR implant following "Administration Instructions" Step 14a through 14h [see *Dosage and Administration (2.2)*].
4. With the iDose TR inserter or viscoelastic cannula, perform a procedural check on the previous implant by gently touching it left to right, right to left, and bottom to top (iris up). Movement of the iris is suggestive of adhesions to the implant.
5. If the previous iDose TR is adhered to the iris, slide the release button on the inserter back to fully open the graspers. Position the graspers between the ribs on the implant and regrasp the body of the implant between the ribs by pushing the release button forward. Slowly rotate the grasped implant 10° clockwise and counterclockwise. Any movement of the iris is suggestive of adhesions. Gently twist and separate the implant from any adhesions while slowly removing the implant.
6. When satisfied that the previous iDose TR is free and clear of the iris, slowly pull the previous implant back from the trabecular meshwork avoiding tension on adjacent ocular structures and withdraw the inserter from the eye.
7. Follow "Administration Instructions" Step 15 [see *Dosage and Administration (2.2)*].

## 2.5 Frequency of Readministration

It is not recommended to readminister an iDose TR more than once per year.

## 3 DOSAGE FORMS AND STRENGTHS

Intracameral implant containing 75 mcg travoprost, pre-loaded in a single-dose inserter.

## 4 CONTRAINDICATIONS

### 4.1 Ocular or Periocular Infections

iDose TR (travoprost intracameral implant) is contraindicated in patients with active or suspected ocular or periocular infections.

### 4.2 Corneal Endothelial Dystrophy

iDose TR is contraindicated in patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae).

### 4.3 Prior Corneal Transplantation

iDose TR is contraindicated in patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]).

### 4.4 Hypersensitivity

iDose TR is contraindicated in patients with hypersensitivity to travoprost or to any other components of the product.

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Iridocorneal Angles

iDose TR should be used with caution in patients with narrow iridocorneal angles (Shaffer grade < 3) or other angle abnormalities (e.g., peripheral anterior synechia, rubeosis iridis) that could impair proper placement of iDose TR at the planned implantation site.

### 5.2 Device Dislocation

Dislocation of the iDose TR has been observed in clinical trials. Patients should be monitored routinely to confirm the location of the iDose TR at the site of administration. If the iDose TR implant becomes dislocated, it should be surgically removed [see *Dosage and Administration* (2.3, 2.4)].

### 5.3 Patients without Baseline Corneal Endothelial Cell Density Prior to Initial Administration

It is not recommended to readminister iDose TR if baseline central corneal endothelial cell density was not established prior to initial administration of iDose TR [see *Warnings and Precautions* (5.4, 5.5)].

### 5.4 Recommended Minimum Corneal Endothelial Cell Density for Readministration

Central corneal endothelial cell density should not be less than the recommended minimum listed in **Table 2** prior to the initial administration of iDose TR and prior to each readministration.

If corneal endothelial cell density was not established prior to the initial administration of iDose TR and only a single eye was implanted, corneal endothelial cell density in the un-implanted contralateral eye meeting the recommended minimum density may be used for eligibility determination for readministration of iDose TR (see **Table 2**).

**Table 2: Recommended Minimum Central Corneal Endothelial Cell Density**

Age	Central Corneal Endothelial Cell Density	
	Phakic Eyes	Pseudophakic Eyes
≤ 45 years	2,200 (cells/mm <sup>2</sup> )	1,540 (cells/mm <sup>2</sup> )
46 to 55 years	2,000 (cells/mm <sup>2</sup> )	1,400 (cells/mm <sup>2</sup> )
56 to 65 years	1,800 (cells/mm <sup>2</sup> )	1,260 (cells/mm <sup>2</sup> )
> 65 years	1,600 (cells/mm <sup>2</sup> )	1,120 (cells/mm <sup>2</sup> )

### 5.5 Corneal Endothelial Cell Loss

iDose TR should be readministered with caution in eyes with 10% or greater loss in central corneal endothelial cell density from pre-administration baseline (adjusted for age-related 1% loss per year and for a 10% loss following an anterior segment surgical procedure [e.g., cataract surgery]).

If baseline corneal endothelial cell density was not established prior to the initial administration of iDose TR and only a single eye is implanted, a 10% threshold level of endothelial cell density loss as a difference of the implanted eye versus un-implanted contralateral eye should be considered before readministering iDose TR.

### 5.6 Macular Edema

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic travoprost, including iDose TR intracameral implant. iDose TR should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

### 5.7 Intraocular Inflammation

Prostaglandin analogs, including iDose TR, have been reported to cause intraocular inflammation. iDose TR should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

### 5.8 Pigmentation

Topical ophthalmic travoprost has been reported to cause increased pigmentation to pigmented tissues. Pigmentation is expected to increase as long as travoprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of travoprost, pigmentation of the iris is likely to be permanent. The long-term effects of increased pigmentation are not known.

Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with travoprost

can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

## 5.9 Endophthalmitis

Intraocular surgical procedures and injections have been associated with endophthalmitis. Proper aseptic technique must always be used with administering iDose TR, and patients should be monitored following the administration.

## 5.10 Magnetic Resonance Imaging (MRI) Conditional

iDose TR is MR Conditional. Patients should be informed that the implant is MR Conditional (as noted on their Patient ID card). If the patient requires magnetic resonance imaging (MRI), they should inform their healthcare provider that they have an iDose TR implanted in their eye.

A patient with the iDose TR may be safely scanned under the following conditions. Failure to follow these conditions may result in injury to the patient.

<b>Parameter</b>	<b>Condition of Use / Information</b>
<b>Nominal Values of Static Magnetic Field (T)</b>	3.0 T or less
<b>Maximum Spatial Field Gradient (T/m and gauss/cm)</b>	40-T/m (4,000-gauss/cm)
<b>Type of RF Excitation</b>	Circularly Polarized (CP) (i.e., Quadrature-Transmission)
<b>Transmit RF Coil Information</b>	Any transmit RF coil may be used
<b>Operating Mode of MR System</b>	Normal Operating Mode
<b>Maximum Whole Body Averaged SAR</b>	2-W/kg (Normal Operating Mode)
<b>Maximum Head SAR</b>	3.2-W/kg (Normal Operating Mode)
<b>Limits on Scan Duration</b>	Whole body averaged SAR of 2-W/kg for 60 minutes of continuous RF exposure (i.e., per pulse sequence or back-to-back sequences/series without breaks)
<b>MR Image Artifact</b>	The presence of this implant produces an imaging artifact. Therefore, carefully select pulse sequence parameters if the implant is located in the area of interest.

## 6 ADVERSE REACTIONS

The following adverse reactions are described elsewhere in the labeling:

- Ocular or periocular infections [see *Contraindications (4.1)*]
- Corneal endothelial dystrophy [see *Contraindications (4.2)*]
- Prior corneal transplantation [see *Contraindications (4.3)*]
- Hypersensitivity [see *Contraindications (4.4)*]

- Device dislocation [see Warnings and Precautions (5.2)]
- Macular edema [see Warnings and Precautions (5.6)]
- Intraocular inflammation [see Warnings and Precautions (5.7)]
- Pigmentation [see Warnings and Precautions (5.8)]
- Endophthalmitis [see Warnings and Precautions (5.9)]

## 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The following adverse events rates are derived from three randomized, double-masked clinical trials in which 868 patients with open angle glaucoma (OAG) or ocular hypertension (OHT) received an iDose TR and were followed for one year. The most commonly reported ocular adverse reactions (2% to 6%) were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity. Ocular adverse reactions reported in less than 2% of patients were conjunctival hemorrhage, photophobia, punctate keratitis, blepharitis, eye irritation, corneal abrasion, device dislocation, vitreous detachment, and foreign body sensation in eyes.

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

#### Risk Summary

There are no adequate and well-controlled studies of iDose TR (travoprost intracameral implant) administration in pregnant women to inform a drug-associated risk.

Subcutaneous administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses.

Advise pregnant women of a potential risk to a fetus. iDose TR should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.

#### Data

##### *Animal Data*

An embryo-fetal development study was conducted in pregnant rats administered travoprost once daily at doses up to 10 mcg/kg by subcutaneous injection from gestation day (GD) 6 to 17, to target the period of organogenesis. At 10 mcg/kg, 116 times the maximum human ocular dose (MHOD) of 1 implant *per eye*, based on body surface area (BSA), assuming sustained travoprost release from the implant for 6 months or 0.0139 mcg/kg/day, travoprost was teratogenic in rats, evidenced by an increase in the incidence of skeletal malformations as well as external and visceral malformations, including fused sternebrae, domed head and hydrocephaly. Travoprost caused post-implantation loss at 10 mcg/kg. The fetal no observed adverse effect level (NOAEL) was 3 mcg/kg (34.5 times the maximum human ocular dose (MHOD) of 1 implant *per eye*, based on BSA).

An embryo-fetal development study was conducted in pregnant mice administered travoprost once daily by subcutaneous injection at doses up to 1 mcg/kg from GD 6 to 16, to target the period of organogenesis. Travoprost induced an increase in post-implantation losses and a decrease in fetal viability in mice at subcutaneous doses > 0.3 mcg/kg. The fetal NOAEL was 0.3 mcg/kg (1.7 times the MHOD based on BSA). The maternal NOAEL was 1 mcg/kg (5.8 times the MHOD based on BSA).

Pre/postnatal development studies were conducted in rats administered travoprost once daily by subcutaneous injection from GD 7 (early embryonic period) to postnatal Day 21 (end of lactation period). At doses of greater than or equal to 0.12 mcg/kg/day (1.4 times the MHOD based on BSA), the incidence of post-natal mortality was increased, and neonatal body weight was decreased. Neonatal development was also affected, evidenced by delayed eye opening, pinna detachment and preputial separation, and by decreased motor activity.

## **8.2 Lactation**

### Risk Summary

There are no data on the effects of travoprost on the breastfed child or milk production. It is not known if travoprost is present in human milk following ophthalmic administration. The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for iDose TR and any potential adverse effects on the breast-fed child from iDose TR.

## **8.4 Pediatric Use**

The safety and effectiveness of iDose TR have not been established in pediatric patients.

## **8.5 Geriatric Use**


No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

## **11 DESCRIPTION**

iDose TR (travoprost intracameral implant) is a sterile intracameral implant containing 75 mcg of travoprost. The intracameral implant consists of a titanium implant reservoir with a membrane controlling the sustained release of travoprost. The sterile implant is pre-loaded in a sterile single-dose inserter to facilitate insertion directly through the trabecular meshwork of the anterior chamber angle into the sclera.

Travoprost is a prostaglandin analog. Its chemical name is 5-heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-, 1-methylethyl ester, (5Z)-. Travoprost has a molecular formula of C<sub>26</sub>H<sub>35</sub>F<sub>3</sub>O<sub>6</sub> and a molecular weight of 500.55 g/mol.

The chemical structure of travoprost is:



Travoprost is a clear, colorless to slightly yellow oil that is very soluble in acetonitrile, methanol, octanol, and chloroform. It is practically insoluble in water.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Travoprost free acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.

### 12.3 Pharmacokinetics

Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea and other intraocular tissues to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the  $\alpha$  (carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13, 14 double bond.

Data from a pharmacokinetic study of 105 subjects evaluating two models of the travoprost intracameral implant with different elution rates have shown that the plasma concentrations of travoprost free acid are below 10 pg/mL (the quantitation limit of the assay, LLOQ) in all subjects at day 10, week 12 and month 12 following administration of iDose TR.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

#### Carcinogenesis

Two-year carcinogenicity studies in mice and rats at subcutaneous doses of 10, 30, or 100 mcg/kg/day did not show any evidence of carcinogenic potential. However, at 100 mcg/kg/day, male rats were only treated for 82 weeks, and the maximum tolerated dose

(MTD) was not reached in the mouse study. The high dose (100 mcg/kg) represents > 500 times the MHOD based on BSA.

### Mutagenesis

Travoprost was not mutagenic in the Ames test, mouse micronucleus test or rat chromosome aberration assay. A slight increase in the mutant frequency was observed in one of two mouse lymphoma assays in the presence of rat S-9 activation enzymes.

### Fertility


Travoprost did not affect mating or fertility indices in male or female rats at subcutaneous doses up to 10 mcg/kg/day (116 times the MHOD based on BSA) At 10 mcg/kg/day (116 times the MHOD based on BSA), the mean number of corpora lutea was reduced, and the post-implantation losses were increased. These effects were not observed at 3 mcg/kg/day (34.5 times the MHOD based on BSA).

## 14 CLINICAL STUDIES


iDose TR was evaluated in two multicenter, 12-month, randomized, parallel-group, double-masked, controlled clinical trials in patients with OAG or OHT. In both trials (GC-010, NCT03519386, and GC-012, NCT03868124), iDose TR was compared to twice-daily topical administration of timolol maleate ophthalmic solution, 0.5%. In the first 3 months following administration, iDose TR demonstrated an IOP change from baseline of -6.6 to -8.4 mmHg in the study eye of patients with a mean baseline IOP of 24 mmHg (see **Figure 6**).

**Figure 6: Change from Baseline in Study Eye IOP (mmHg) and Treatment Difference**

### Study GC-010



### Study GC-012



iDose TR demonstrated non-inferiority to timolol ophthalmic solution in IOP reduction during the first 3 months. Subsequently, iDose TR did not demonstrate non-inferiority over the next 9 months.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

iDose TR (travoprost intracameral implant) (NDC 25357-100-01) is provided sterile and pre-loaded in a sterile, single-dose inserter that is packaged in a blister tray sealed with a Tyvek lid. Implants are individually serialized and the serial number is provided on the tray lid.

The tray is sealed inside of a transparent plastic pouch along with an oxygen scavenger packet, which is packaged inside a unit carton. Tamper evidence is provided by a seal on both ends of the carton.

### Storage:

Store at 2°C to 25°C (36°F to 77°F). Do not freeze.

## 17 PATIENT COUNSELING INFORMATION

### Intraocular Inflammation or Endophthalmitis

Advise patients about the potential risk for complications including, but not limited to, the development of intraocular inflammation or endophthalmitis [see *Warnings and Precautions* (5.6, 5.7, 5.9)].

### Potential for Pigmentation

Advise patients about the potential for increased brown pigmentation of the iris, which may be permanent [see *Warnings and Precautions* (5.8)].

### MR Conditional


Advise patients that the implant is MR Conditional (as noted on their Patient ID card), and that if they require magnetic resonance imaging (MRI), they should inform their healthcare provider that they have iDose TR implanted in their eye [see *Warnings and*

Precautions (5.10)].

#### When to Seek Physician Advice

Advise patients that if the eye becomes red, sensitive to light, painful, or develops a change in vision, they should seek immediate care from an ophthalmologist [see *Warnings and Precautions (5.2, 5.7, 5.9)*].

Symbols that are included in the labeling of this product.

<b>Symbol</b>	<b>Definition</b>
	Catalogue/Model Number
	Serial Number
	Lot Number
	Do not re-use
 yyyy-mm	Use-by date (year-month)
	Do not re-sterilize
	See package insert for Full Prescribing Information
	Temperature limit
	Sterilized by e-beam irradiation
<b>RX Only</b>	For prescription use only
	Do not use if package is damaged
	MR Conditional


**Manufactured by Glaukos Corp., 229 Avenida Fabricante, San Clemente, CA 92672**

© 2026 Glaukos. All rights reserved.

Glaukos and iDose are registered trademarks of Glaukos Corporation. All other trademarks are the property of their respective owners.

Patents [www.glaukos.com/patents](http://www.glaukos.com/patents)

**PRINCIPAL DISPLAY PANEL - NDC: 25357-100-01 - 75 mcg Carton Labeling**



**PRINCIPAL DISPLAY PANEL - NDC: 25357-100-01 - 75 mcg Carton Labeling - Physician Sample**

NDC 25357-100-99

SAMPLE - NOT FOR SALE

iDose® TR  
(travoprost intracameral implant) 75 mcg

GLAUKOS®

Rx Only



## IDOSE TR

travoprost intracameral implant

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:25357-100
<b>Route of Administration</b>	INTRACAMERAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
TRAVOPROST (UNII: WJ68R08KX9) (TRAVOPROST - UNII:WJ68R08KX9)	TRAVOPROST	75 ug

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:25357-100-01	1 in 1 CARTON	12/13/2023	
1		1 in 1 POUCH		
1		1 in 1 TRAY		
1		1 in 1 CANISTER; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		
2	NDC:25357-100-99	1 in 1 CARTON	02/17/2026	
2		1 in 1 POUCH		
2		1 in 1 TRAY		
2		1 in 1 CANISTER; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA218010	12/13/2023	

**Labeler** - Glaukos Corporation (012835406)

**Registrant** - Glaukos Corporation (080653551)

## Establishment

Name	Address	ID/FEI	Business Operations
Glaukos Corporation		080653551	MANUFACTURE(25357-100) , ANALYSIS(25357-100) , LABEL(25357-100) , PACK(25357-100)

Revised: 2/2026

Glaukos Corporation